Physicians' Academy for Cardiovascular Education

Reassuring safety data with investigational lipid-modifying agent

3' education - May 24, 2015 - ISA2015, Amsterdam - David Kallend



David Kallend (The Medicines Company, Parsippany, NJ, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015

ISA2015 | Clinical Breakthroughs Dr. Kallend shares data of a phase I trial with ApoA1-Milano-POPC (MDCO216), which was well-tolerated and showed an increase in efflux in patients with recent CAD but who are clinically stable.

Share this page with your colleagues and friends: